“Small-caps remain a very key component of the market’s comeback story,” commented Instinet’s Executive Director Frank Cappelleri. “Seeing demand reignite in the most speculative names would give us a strong indication that the bid can continue. And vice versa.”
cbdMD, a Level Brands company (NYSE American: LEVB), has launched a new CBD oil vape brand – Mingo Rad.
Why It Matters: Mingo Rad dedicates its resources to offering superior CBD packed with innovative, bold flavors. Sourcing exclusively from domestic hemp and crafted with a unique manufacturing process, Mingo Rad offers a non-GMO, gluten- and THC-free broad-spectrum product. Mingo Rad CBD vape oils deliver a smooth, satisfying vape experience, making it easier than ever to improve one's overall health and wellness.
Key Quote: "Mingo Rad offerings are bright, vibrant, and promote Naturally Good Vibes – with a natural and beneficial alternative to traditional vape products.” – Caryn Dunayer, Co-Founder & President
Disclosure
Level Brands (NYSE American: LEVB) is a client of RedChip Companies. LEVB agreed to pay RedChip a monthly cash fee and 5,000 shares of Rule 144 stock for four months of RedChip investor awareness services.
Cuentas (OTCQB: CUEN), an emerging fintech leader serving the underbanked and unbanked Latino markets, will host an investor webinar and live Q and A session Thursday, March 28, 2019 at 11 am Eastern.
The webinar will feature a presentation by Michael De Prado, Founder, President, COO, and Director of Cuentas, who will discuss the competitive positioning of CUEN, the Company's growth opportunities, value proposition, and more. Following the presentation, Mr. De Prado will take questions from attendees.
About Cuentas (OTCQB: CUEN)
Market cap: $4 million
Cuentas provides innovative mobile banking and telecommunications solutions to underserved, unbanked, and emerging markets
The Company’s portfolio of solutions across multiple fintech verticals meet the highest-volume services needed by the estimated 70 million underbanked people in the United States. Underbanked people represent more than $1 trillion in purchasing power
Cuentas’s General Purpose Reloadable (GPR) cards provide customers with comprehensive, cross-border, open-loop fintech solutions. Reloadable Visa debit cards provide access to banking, on-line purchasing, and telecom/data/video services
Partnering with Incomm, $14B global leader in prepaid cards and payment solutions, Cuentas provides customers banking and GPR reloading facilities at more than 200,000 locations across the United States (Wal-Mart, 7-Eleven, Walgreens, Family Dollar, and more)
As the Company continues to execute, awareness of its rapid growth should spread, leading to broader participation in the stock and a more realistic and higher valuation
For questions about the webinar, contact Bruce Haase (407-712-8965 or bruce@redchip.com).
Cuentas (OTCQB: CUEN) agreed to pay RedChip Companies, Inc. 10,000 shares of Rule 144 stock and a monthly cash fee for three (3) months of investor relation awareness services.
MYnd Analytics (NASDAQ: MYND), a technology-enabled telepsychiatry and teletherapy company providing enhanced access to behavioral-health services, will host a group call Thursday, March 28, 2019 at 11 am Eastern. Duration: 20 minutes.
For more information about the call (which will not be archived), call Craig Brelsford, at (407) 571-0902, or email him at craig@redchip.com.
The group call will feature a presentation by Robin L. Smith, Chairman of the Board of MYND, and Patrick Herguth, Chief Executive Officer and Director. Smith and Herguth will discuss recent developments and key upcoming milestones.
About MYnd Analytics (NASDAQ: MYND)
Market cap: $13 million
The MYnd Psychiatric EEG Evaluation Registry (PEER) is a predictive analytics decision-support tool that helps physicians reduce trial-and-error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient's unique brain markers, reducing both cost and time of treatment
MYND's wholly owned subsidiary, Arcadian Telepsychiatry Services, LLC, provides a suite of complementary telemedicine services that can be combined with PEER, among them telepsychiatry, teletherapy, digital patient screening, curbside consultation, and on-demand services
MYND's customers include major health plans, health systems, and community-based organizations. MYND's tele-behavioral health services are now offered through the Magellan Healthcare provider network—evidence of the power of MYND's technology and its best-in-class platform
In January 2019, MYND announced a merger agreement with Emmaus Life Sciences, developer of the first FDA-approved drug for the treatment of sickle-cell disease. MYND shareholders will own 5.9% of Emmaus, and MYnd Analytics will be spun off as an independent company, providing shareholders with upside potential in two exciting growth stories
MYnd Analytics, Inc. (NASDAQ: MYND) is a client of RedChip Companies, Inc. MYND agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services.
• Achieved the final milestone in the Phase 3 long-term safety study of Qtrypta, with a cohort of patients completing 12 months on study drug
• Announced the treatment of nearly 6,000 migraines in our long-term safety study
• Received patent covering the use of Qtrypta as an acute treatment for migraine and cluster headache, providing protection through 2037
• Completed contracts for the outsourcing of manufacturing to established and FDA experienced contract manufacturers
Key Quote: “Following the completion of our Phase 3 clinical program for QtryptaTM (M207), we see a clear path to the filing of our NDA in the fourth quarter of this year. As we look to 2019, we plan to build on these accomplishments with the initiation of partnering discussions for the marketing and distribution of Qtrypta, the expansion of our pipeline and the further development of our unique intracutaneous microneedle system for the delivery of biologic agents, where we can offer an alternative to intravenous (IV), intramuscular (IM), and subcutaneous (SC) injections.” John Walker, Chairman and CEO, Zosano Pharma Corporation (NASDAQ: ZSAN)
The Backstory: Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing administration of therapeutics to patients using its intracutaneous delivery system, which consists of titanium microneedles coated with drug that can enable rapid systemic administration to patients. The company’s lead product candidate is QtryptaTM (M207), which is Zosano’s proprietary formulation of zolmitriptan delivered via its intracutaneous delivery technology for the treatment of migraine disease. In February 2017, the company announced statistically significant results from the ZOTRIP pivotal study and in February 2019, Zosano announced the completion of the final milestone in its long-term safety study and its expectations to file an NDA for Qtrypta in the fourth quarter of 2019. Learn more at www.zosanopharma.com.
• Total revenues increased by 20.9% year-on-year to RMB1, 803.2M (US $262.3M) in 4Q18
• Net income increased by 15.1% year-on-year to RMB2, 491.3M (US $362.3M), or RMB7.74 (US$1.13) per diluted ADS in FY18
Key Quote: “Throughout 2018, as a result of our commitment to delivering risk adjusted returns and an overall conservative risk management approach, our asset quality was maintained within our target levels. On regulatory risk, there were various new regulations and guidelines issued in 2018 for the sector.” Min Luo, Founder, Chairman and Chief Executive Officer of Qudian (NYSE: QD)
Qudian is a leading provider of online small consumer credit in China. The Company uses big data-enabled technologies, such as artificial intelligence and machine learning, to transform the consumer finance experience in China. With the mission to use technology to make personalized credit accessible, Qudian targets hundreds of millions of young, mobile-active consumers in China who need access to small credit for their discretionary spending or budget auto financing solutions but are underserved by traditional financial institutions due to lack of traditional credit data. Qudian's data technology capabilities combined with its operating efficiencies allow Qudian to understand prospective borrowers from different behavioral and transactional perspectives, assess their credit profiles with regard to both their willingness and ability to repay and offer them instantaneous and affordable credit products with customized terms, and distinguish Qudian's business and offerings.
Revenue for the year ended December 31, 2018 was $21.5M, compared to $14.8M for the year ended December 31, 2017. This increase was driven by the expansion of the company’s profiling services business and further progress on our collaborative development programs.
In addition, established HTG Molecular Diagnostics France, SARL (“HTG France”), a wholly-owned French subsidiary, encompassing an applications laboratory in Sausheim, France. HTG France is expected to facilitate HTG’s ability to generate molecular diagnostic revenue in Europe and to improve its responsiveness to its growing customer base in Europe.
Entered into an amendment and extension to HTG’s second precision diagnostic partnership program under the company’s Master Assay Development, Commercialization and Manufacturing Agreement with QIAGEN Manchester Limited in February 2019.
Expanded HTG’s molecular diagnostic leadership team to include Dr. Maureen Cronin, CSO, and, most recently, Laura Beggrow, President, Diagnostics, and also made several, experienced development team hires, expected to be based in a San Francisco Bay Area California facility.
Key Quote: “We entered 2018 with the momentum of our collaboration program success and determined to grow our profiling business further, by accelerating customer adoption, expanding our Biopharma pipeline, initiating commercialization of our CE/IVD products in Europe and strengthening our balance sheet.” TJ Johnson, CEO of HTG
The Backstory: HTG is focused on advancing precision medicine. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options.
Quote of the Week
"Get to know management, look for intelligence, a high level of integrity, strong communication skills, and make sure they understand their products and business well."
- Charles Diker, Diker Management
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures.
